Medical device and MedTech insights, news, tips and more

Cardiac Rehabilitation Can Save Your Life – Why Don’t More Heart Patients Sign Up?

July 27, 2016

Cardiac Rehabilitation

When Mario Oikonomides was 38 years old he had a massive heart attack. About a month later, after he’d recuperated from the emergency, his doctors sent him to a cardiac rehabilitation program, where he learned about the role physical activity can play in reducing cardiac risk.

Cardiac Rehabilitation“I never exercised before,” Oikonomides says. “I became addicted to exercising.” The program, overseen by a medical team, also checked up on his medications, provided nutrition counseling and offered other help and coaching in the fraught weeks and months after his hospitalization.

Oikonomides is 69 now and lives in Charlottesville, Va. When he recently needed bypass surgery, long decades after that heart attack, he again signed up for a rehabilitation program as soon as he could.

“I bought myself 30 years of healthy life as a result of cardiac rehab,” he says.

But, despite many years of research showing that joining a cardiac rehabilitation program can help heart patients heal faster and even live longer, Oikonomides is among a minority of patients who take advantage of such programs; fewer than a third do.

Why is rehab such a hard sell? Blame it on a number of factors, doctors say.

Some patients have to travel a long way to the nearest program; work schedules keep others from joining. Uninsured patients often can’t afford it. And even those with insurance can be stopped short by copayments that can be $20, $40 — or even $50 a class.

“The number one barrier is the cost of the copay, which is frustrating,” says Dr. Ellen Keeley, a cardiologist at the University of Virginia Health System.

Read Full Article – Source: Cardiac Rehab Saves Lives. So Why Don’t More Heart Patients Sign Up? : Shots – Health News : NPR

More insights

November 11, 2024
What is the Difference Between MedTech and TechMed?  
Learn More
March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.